Brazilian Pharmaceutical Union Chemical Union
Material will be sent to Russia for quality control.
“This stage of the project, launched last October, is an important step in the transfer of technology, necessary to guarantee the production of the Russian vaccine in Brazil”, the embassy published in its profile on social networks.
This batch will be sent in full to the National Research Center for Epidemiology and Microbiology Gamaleya, which developed the immunizer, for quality control.
In early January, União Química received cellular material to manufacture the vaccine and began to produce an experimental batch of the active components of the immunizer for research purposes. União Química, which represents the Russian Direct Investment Fund (RDIF) in Brazil, filed with Anvisa a new application for registration of Sputnik V on March 26. According to the legislation in force, such requests must be considered within a period of seven days, but this can be extended if some required documents are not presented in time. The day after the new request, Anvisa suspended the review for an indefinite period, claiming that it had not yet received part of the necessary documentation.
This is not, however, the first time that the analysis of the emergency use of the Russian vaccine in Brazil has been postponed. The president of União Química, Fernando Marques, had previously accused the agency of deliberate delays for the benefit of other manufacturers of vaccines against covid-19.
ALSO READ: Anvisa certifies the Brazilian Sputnik V vaccine factory
We authorize the reproduction of all of our texts on the condition that the active link to the Russia Beyond original is published together.
Get the latest news delivered to your inbox
Follow us on social media networks